74 results about "Therapeutic action" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The application provides a preparation of a sema7A monoclonal antibody 8A12 and a treatment effect of the sema7A monoclonal antibody 8A12 on lupus nephritis, wherein the CDR-H1 of the heavy chain variable region of the monoclonal antibody 8A12 is an amino acid sequence shown in SEQ ID No. 1, the CDR-H2 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 2, and the CDR-H3 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 3; the CDR-L1 of the light chain variable region of the monoclonal antibody 8A12 is an amino acid sequence shown in SEQ ID No. 4, the CDR-L2 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 5, and the CDR-L3 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 6. The monoclonal antibody 8A12 can effectively inhibit the expression up-regulation of IL-1beta, TNF-alpha and IL-6 caused by Sema7A recombinant protein, can effectively inhibit the macrophage inflammatory response induced by Sema7A, and can continuously and effectively reduce serum anti-double-stranded DNA antibodies and kidney damage of lupus mice. The monoclonal antibody 8A12 can be used for preparing a pharmaceutical composition for preventing and / or treating systemic lupus erythematosus and / or lupus nephritis thereof.

The present invention relates to immunoglobulin single variable domains (ISVDs) for the treatment of diseases by the enteral, e.g. oral, delivery. In particular, the present invention provides ISVDs comprising sequences with a high percentage of sequence identity to SEQ ID NO: 1 for such enteral administration. Such sequences were identified as extraordinarily stable in the gastrointestinal tract, which prevents their degradation and thereby allows them to exert a strong therapeutic effect.

The invention discloses a nucleotide for inhibiting expression of ILKAP (Interleukin-7-Kinase Associated Protein) related circular RNA (Ribonucleic Acid) and application of the nucleotide, and the nucleotide is characterized in that the nucleotide sequence is CGUCAGUACUCGGGUUUCA, and the expression level of hsacirc0001116 can be specifically and obviously reduced. Experimental results prove that the nucleic acid molecule can effectively interfere with the expression of hsacirc0001116 in human non-small cell lung cancer A549 cells, and can significantly inhibit the survival of lung cancer cells. In addition, when the nucleic acid molecule is combined with an existing antitumor drug for use, a synergistic treatment effect can be generated.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

An antibody-conjugated liposome, particularly a nanoparticle. The surface of the nanoparticle contains antibodies. The number of the antibodies is 5-60, preferably 5-50, and more preferably 5-40. The nanoparticle, for example, a liposome, can more effectively exert a therapeutic effect on tumor and improve multidrug resistance of tumor, thereby overcoming the technical prejudice that it is commonly considered that the more antibodies on a surface of a liposome, the better the target cell binding effect, and laying a foundation for further clinical development.An antibody-conjugated liposome, particularly a nanoparticle, the surface of which contains antibodies, and the number of the antibodies is 5-60, preferably 5-50, and more preferably 5-40. The nanoparticle, such as a liposome, can more effectively exert a therapeutic effect on tumors and reduce the multidrug resistance of tumors. This overcomes the generally accepted technical bias that more antibodies on the surface of a liposome lead to better binding with target cells, thereby laying the foundation for further clinical development.

The application discloses application of a miR-8069 inhibitor and belongs to the technical field of biological medicines.The inventor of the application finds that the expression of miR-8069 in the plasma of IS patients is abnormally increased in the research on the pathogenesis of IS, and through further cell experiments, it is found that inhibiting the expression of miR-8069 can effectively improve the adverse effects of OGD / R treatment on cell viability, apoptosis and ROS, and has a significant therapeutic effect on IS. Cell damage induced by OGD / R is often used as a model of cerebral stroke in vitro in research. The miR-8069 inhibitor disclosed by the application is used for preparing a medicine for treating cerebral stroke, and the nucleotide sequence is as follows: ACCGCCGACCGCCCCCAACCAUCC.

The invention discloses application of a miR-3960 inhibitor, and belongs to the technical field of biological medicines. The invention aims to find and discover miRNA markers related to AD diagnosis and treatment. Researches on AD pathogenesis discover that expression of the miR-3960 is significantly increased in AD patients, and further cell experiments discover that inhibition of the expression of the miR-3960 significantly improves the influence of A beta1-42 on cell viability, apoptosis, ROS and APP proteins, and the miR-3960 has a significant therapeutic effect on AD. A beta1-42 is a core component of amyloid plaque in the brain of an AD patient, and is widely applied to construction of AD cell models and animal models so as to research pathogenesis and drug evaluation of AD. The miR-3960 inhibitor is used for preparing a medicine for treating the Alzheimer's disease, and the nucleotide sequence of the miR-3960 inhibitor is CCCCCGCCUCCGCCGCCGCC.

The invention relates to the technical field of medicines, in particular to application of a neuropeptide Y1 receptor antagonist in preparation of a hereditary polycystic kidney disease treatment medicine. The neuropeptide Y1 receptor antagonist is selected from a compound BIBO3304 which plays a role in blocking combination of neuropeptide Y (NPY) and a Y1 receptor subtype thereof. On the basis that early-stage histopathology, high-throughput sequencing, cytobiology and molecular biology are combined with in-vitro cell culture and in-vivo animal experiments, the potential treatment effect of the neuropeptide Y1 receptor antagonist in preparation of hereditary polycystic kidney disease treatment drugs is provided, and a new basis is provided for hereditary polycystic kidney disease treatment.

This invention discloses the application of substances that inhibit Trx1 nitration in the preparation of drugs for treating Trx1 nitration-related diseases. This invention reveals for the first time that nitration modification of tyrosine residue 49 (Y49) of the Trx1 protein is a key pathological step in diseases such as ischemic stroke and myocardial ischemia-reperfusion injury. Inhibiting nitration at this site can effectively restore Trx1 reductase activity, enhance the binding of Trx1 to ASK1, and block the downstream ASK1-p38 / JNK apoptosis signaling pathway, thereby exerting a therapeutic effect. This invention provides a novel treatment strategy for Trx1 nitration-related diseases.

The application discloses an application of a miR-4680-3p inhibitor and belongs to the technical field of biological medicines.The inventor of the application finds that the expression of miR-4680-3p in the plasma of IS patients is abnormally increased in the research on the pathogenesis of IS, and through further cell experiments, it is found that inhibiting the expression of miR-4680-3p can effectively improve the adverse effects of OGD / R treatment on cell viability, apoptosis and ROS, and has a significant therapeutic effect on IS. Cell damage induced by OGD / R is often used as a classic model of cerebral apoplexy in vitro in research. The miR-4680-3p inhibitor disclosed by the application is used for preparing a medicine for treating ischemic apoplexy, and the nucleotide sequence of the miR-4680-3p inhibitor is as follows: UAACAACUCUUACAAUUCAGA.

Provided herein are compositions of chimeric shuttle-binder-effector fusion proteins with components related to modulating endogenous cytotoxic effector mechanisms, which are useful for therapeutic effects on predetermined target molecules. These shuttle-binder-effector proteins also have specific epitope binding affinities for these target molecules. Compositions for modified cells expressing these chimeric shuttle-binder-effector fusion proteins are also provided. Methods for the modification of cells to express these chimeric shuttle-binder-effector fusion proteins and for delivering the chimeric shuttle-binder-effector fusion proteins into target cells using the lytic granule cellular mechanisms in these modified cells are also provided.

The invention discloses a Toll-like receptor (TLR) agonist / organic photosensitizer protein nano-composite as well as a preparation method and application of the Toll-like receptor (TLR) agonist / organic photosensitizer protein nano-composite. In order to overcome the defects of short blood half-life period, low bioavailability and the like of the existing TLR agonist, the protein nano-composite is obtained by forming a compound in a protein cavity by using the TLR agonist and an organic photosensitizer, and has tumor and lymph node dual-targeting characteristics. The protein nano-composite is simple in preparation method, mild in condition, free of an organic solvent, uniform in particle size and has a pH-responsive drug release behavior, and the protein nano-composite is prepared by a one-step method with water as a solvent. Based on an active targeting mechanism mediated by an albumin binding receptor and an active uptake mechanism of antigen presenting cells to albumin, the nano-composite has tumor and lymph node dual-targeting characteristics, has immunotherapy and light therapy effects under irradiation of near-infrared light, and has a good application prospect from two aspects of short-term quick action and long-term body immunity improvement. Tumor growth is effectively restrained, and tumors are expected to be radically treated.

The invention provides an application of an ethyl acetate extract of angelica keiskei in preparation of a medicine for treating or preventing HCMV (human cytomegalovirus) infection. A preparation method of the angelica keiskei ethyl acetate extract comprises the following steps: taking fresh angelica keiskei medicinal material, air-drying, grinding into coarse powder, soaking with ethanol for 48 hours, percolating and extracting, collecting percolate, concentrating under reduced pressure until no ethanol smell exists, dispersing the obtained alcohol extract with warm water, adding isopyknic ethyl acetate for extraction, concentrating under reduced pressure until no ethyl acetate smell exists, and drying to obtain the angelica keiskei ethyl acetate extract. The angelica keiskei ethyl acetate extract is named as EEAK. According to the present invention, the research results show that the angelica keiskei ethyl acetate extract EEAK provides significant inhibition effects for the DNA copy numbers of the immediate early-stage protein IE1 / 2, the early-stage protein p52, the immediate early-stage gene UL123, the early-stage gene UL44 and the later-stage gene UL32 of the HCMV, provides significant prevention and treatment effects for the HCMV, has characteristics of low toxic-side effect, safety, effectiveness and good application prospects, and can be used for the HCMV infection.

The invention discloses an application of a substance taking Angpt18 as a target in preparation of a medicine for treating and delaying senescence, and the key regulation effect of an Angpt18 gene in the occurrence and progression process of normal senescence and senescence-related diseases is found for the first time through systematic and in-depth research; further experiments prove that by inhibiting or down-regulating the expression of the Angpt18 gene, the senescence process can be obviously delayed, and the expressions such as hypomnesia and behavioral ability decline in the senescence process can be effectively improved. Therefore, the Angpt18 gene can be used as an important intervention target for senescence and related diseases thereof, can be used for developing drugs with senescence delaying or treatment effects, can also be used as a biomarker for evaluating the senescence degree and diagnosing and prognosing the related diseases of senescence, and has wide application prospects and clinical transformation values.

The present invention relates to a composition comprising HAPLN1 as an active ingredient for preventing or treating senile degenerative brain diseases. Specifically, recombinant human HAPLN1 protein (rhHAPLN1) lowers the protein level of p16 in cultured human astrocytes to inhibit cellular senescence caused by the accumulation of beta amyloid peptides, and further inhibits phosphorylation (p-p38 MAPK) of p38 MAPK protein, thereby also having the possibility of inhibiting inflammatory responses associated with the onset of Alzheimer's disease and Parkinson's disease. In addition, the recombinant human HAPLN1 protein (rhHAPLN1) exhibits significant memory and learning improvement effects in in vivo experiments performed using a mouse acute Alzheimer's disease model, and thus can be expected to exhibit preventive and therapeutic effects against Alzheimer's disease that may occur with aging and the like. In addition, the inhibitory effect of the rhHAPLN1 protein on cellular senescence and inflammatory responses of astrocytes can provide a very important clue for establishing prevention and treatment strategies not only for aging itself but also for brain functions, motor behaviors, memory, seizures, dementia, brain tumors, and the like.

The invention relates to the technical field of biological medicine, in particular to functionalized lipopeptide and a preparation method thereof, a functionalized lipopeptide-assisted nucleic acid drug lipid nano delivery system and application thereof. The functionalized lipopeptide is a compound formed by functionalized polyethylene glycol-lipid and partially or completely exposed amino groups of the functionalized hybrid polypeptide through a click chemical reaction or a Michael addition reaction; the functionalized hybrid polypeptide is a compound formed by an esterification reaction of an N-hydroxysuccinimide-polyethylene glycol-group and partially or completely exposed amino groups of the functionalized polypeptide. The lipopeptide provided by the invention is simple in preparation process and low in toxicity, and the lipopeptide-assisted nucleic acid drug lipid nano delivery system can realize high-efficiency delivery of various nucleic acid molecules such as siRNA, mRNA and DNA in vitro and in vivo and has a treatment effect on various diseases.

The present application relates to the technical field of RPS4X, and particularly relates to siRNA targeting RPS4X gene, LAMB3-PI3K-AKT signal pathway inhibitor, ovarian cancer drug and application. The siRNA targets and interferes with RPS4X gene expression. The siRNA and the LAMB3-PI3K-AKT signal pathway inhibitor are used on in-vitro ovarian cancer cells and in-vivo ovarian cancer tissues, and both have the effect of inhibiting proliferation, migration and invasion. The various siRNAs targeting RPS4X gene and the LAMB3-PI3K-AKT signal pathway inhibitors provided in the embodiments have the effects of promoting apoptosis of ovarian cancer cells and tissues and inhibiting tumor angiogenesis, have obvious ovarian cancer prevention and treatment effects, and have the application prospect of developing as ovarian cancer drugs.

The invention discloses a method for preparing tea polysaccharide through fungal fermentation and application of the tea polysaccharide in oxidation resistance and HCMV resistance. The fermented tea polysaccharide FTP is an acidic polysaccharide, can significantly inhibit expression of immediate early-stage protein IE1 / 2 and early-stage protein p52 of HCMV, and reduces DNA copy numbers of immediate early-stage gene UL123, early-stage gene UL44 and late-stage gene UL32, so that the fermented tea polysaccharide FTP shows clear prevention and treatment effects on HCMV infection; meanwhile, the polysaccharide also shows excellent antioxidant activity, and has relatively high scavenging capacity on DPPH free radicals and ABTS cation free radicals. The fermented tea polysaccharide has antiviral and antioxidant dual biological activities, is high in safety and low in toxic and side effects, provides a new natural source candidate component for developing anti-HCMV medicines, and has a good application prospect.

The invention belongs to the technical field of stem cell biological medicine, and particularly relates to application of uterine blood mesenchymal stem cell outer vesicles. According to the application, external vesicles (MenSC-EVs) derived from MenSC are used as active ingredients, the MenSC-EVs effectively relieve the hepatic fibrosis condition of a mouse, the key effect of a Thbs1 / Cd36 signal on mediating intercellular communication in a fibrosis hepatic microenvironment is disclosed, and the therapeutic effect of the MenSC-EV on hepatic fibrosis and a potential molecular mechanism of the MenSC-EV are explored and confirmed.

The application provides a fusion protein, a gene, a recombinant vector, a recombinant cell, brain-targeting exosomes and application thereof, and relates to the field of drug treatment. The exosomes can be precisely targeted to a target site as a drug delivery carrier to play a therapeutic role of genes and chemical drugs. In the application, a gene sequence of a highly expressed NCAM gene in microglial cells, a segment of a simulation peptide NMP2, and a gene sequence of an exosome membrane protein Lamp2b are connected, an expression vector is constructed, and the expression vector is transfected into a packaging cell, so that the NCAM simulation peptide NMP2 is presented on the surface of the exosomes, the exosomes have the ability of targeting microglial cells, the exosomes can carry therapeutic drugs to pass through the blood-brain barrier and enter the lesion area in the brain, regulate the microenvironment, promote the clearance of A beta deposition, and can be used for the treatment of Alzheimer's disease.

This invention relates to the field of biomedical technology, and more particularly to a *Lactobacillus paracasei* strain with significant hypoglycemic effects. This invention develops an engineered bacterium that continuously secretes a mutant GLP-1 protein, capable of expressing a fusion peptide containing a signal peptide, an enhancing peptide, and the mutant GLP-1 protein. It exhibits good passage stability and can exert a dual therapeutic effect on type 2 diabetes through continuous secretion of the mutant GLP-1 protein and regulation of the gut microbiota. The engineered bacterium of this invention can be used to prepare oral pharmaceutical formulations. Therefore, this invention provides a new technical means for developing non-invasive, cost-effective, and efficient drug delivery strategies targeting GLP-1, and has broad application prospects.

Ischemic heart disease is a leading cause of death and reduced quality of life worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), many patients with MI develop chronic heart failure over time. We previously reported that human recombinant ANGPTL4 counteracts ischemia-induced vascular endothelial growth factor signaling and disruption of endothelial cell-cell adhesion, thereby inhibiting vascular permeability. We were able to demonstrate that ANGPTL4 administration before MI resulted in protection of the coronary capillary network, no-reflow syndrome, and reduced infarct size in mice. We also demonstrated that the therapeutic effects observed with ANGPTL4 under ischemic conditions were caused by the FLD fragment, not the CCD fragment (WO 2016 / 110498). To further examine the therapeutic potential of the FLD fragment of ANGPTL4 at the onset of reperfusion, we herein used a porcine model, a clinically relevant model of acute myocardial infarction that can be easily and safely translated into patient treatment. We demonstrated that local (antegrade) delivery of the FLD ANGPTL4 to infarcted porcine hearts can efficiently target the lesion site in a clinically relevant manner. A single administration of the FLD of ANGPTL4 improved cardiac function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments, coupled with complementary mouse studies, demonstrated myocardial protection. Thus, a single administration of the FLD of ANGPTL4 can reduce ischemia-reperfusion injury and protect against adverse postischemic cardiac remodeling and subsequent ischemic heart failure.

Provided is a thrombolytic agent for ‘intravascular thrombus’, and more particularly, to a thrombolytic agent having a thrombo-recognition domain and a thrombolytic domain. It also relates to a polypeptide for thrombolysis of an intravascular thrombus, a gene for that polypeptide, and a pharmaceutical composition containing the same. The polypeptide that recognizes ‘intravascular thrombus’ and dissolves thrombus of the present invention is characterized in that it consists of a thrombolytic domain comprising the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 and a thrombo-recognition domain comprising the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4. According to the present invention, the polypeptide for dissolving thrombus by recognizing ‘intravascular thrombus’ dissolves thrombus in the blood of a mammal without serious bleeding side effects has a preventive and therapeutic effect on thrombosis, thus preventing thrombosis and related diseases.

The invention relates to a fusion protein, a recombinant vector, a host cell and application thereof. According to the fusion protein, a complementary fluorescent molecule is inserted into a proinsulin precursor, the complementary fluorescent molecule is composed of a first fragment and a second fragment, the first fragment is located between a B peptide chain and a C peptide chain of the proinsulin precursor, and the second fragment is connected to the C tail end of an A peptide chain of the proinsulin precursor. The fusion protein can be folded into insulin with fluorescence after being sheared by the signal peptide and the C peptide chain, and can be used for indicating the content of insulin in cells. The recombinant expression vector or the host cell can be used for constructing a cell model. The cell model is used for screening compounds capable of promoting proinsulin maturation and increasing insulin content, and a lead compound is screened by using a high-throughput compound library screening method so as to evaluate the potential therapeutic effect or side effect of the lead compound and serve as a candidate molecule for subsequent drug development and commercialization.

This invention provides the application of Ginkgo biloba polysaccharide in the preparation of drugs for treating and / or preventing HCMV. Ginkgo biloba L. GP) for HCMV immediate early protein IE1 / 2, early protein p52, and immediate early gene UL123 Early genes UL44 and late genes UL32 It has a significant inhibitory effect on DNA copy number, and has significant preventive and therapeutic effects on HCMV infection. Moreover, GP has few toxic side effects, is safe and effective, and can be used for HCMV infection, showing good application prospects.

The invention provides recombinant lactobacillus plantarum for expressing porcine epidemic diarrhea virus S1 protein as well as a preparation method and application of the recombinant lactobacillus plantarum, and belongs to the technical field of preparation of porcine epidemic diarrhea virus vaccines. The recombinant lactobacillus plantarum provided by the invention contains a recombinant vector for expressing a PEDV tS1 fusion gene, and the PEDV tS1 fusion gene comprises a PEDV tS1 structural domain, an endogenous signal peptide 1320 and a dendritic cell targeting peptide DCpep. After the recombinant lactobacillus plantarum provided by the invention is used as a mucosal vaccine through nasal dripping, not only can a codon be prevented from being repeatedly optimized, but also strong cross-species immune response can be induced, pathogen specificity sIgA can be generated, mucosal immunity can be effectively activated, and the induced antibody has the activity of neutralizing PEDV (porcine epidemic diarrhea virus). The recombinant lactobacillus plantarum provided by the invention has a treatment effect.

An intraoperative probe combines Raman spectroscopy, shear wave elastography (SWE), and photodynamic therapy (PDT), preferably in a single hand-held device with real- time machine learning analysis. The machine learning independently analyzes and then fuses the data from different modalities for real-time cancer diagnostic predictions. The approach herein leverages simultaneous (or near-simultaneous) collection and real-time processing of Raman and SWE data for immediate cancer diagnostic feedback and therapeutic action. The hand-held device is precisely configured to target the same focal point with three different modalities - Raman, SWE, and PDT - by positioning the modalities within the device into the same location, either with an array of mirrors or an automatic or manual rotation mechanism.

The invention discloses application of a miR-4716-3p inhibitor, and belongs to the technical field of biological medicines. The miR-4716-3p inhibitor is used for preparing a medicine for treating the Parkinson's disease, and the nucleotide sequence of the miR-4716-3p inhibitor is UCUCAUGUUCCUUCCCCCUU. According to the application disclosed by the invention, the research on PD pathogenesis discovers that the expression of the miR-4716-3p in the plasma of a PD patient is remarkably increased for the first time, and further cell experiments discover that the influence of MPP + on cell viability, apoptosis, ROS, p-alpha-syn and TH protein can be remarkably improved by inhibiting the expression of the miR-4716-3p, so that the miR-4716-3p has a remarkable treatment effect on PD.

The invention provides a miR-671-5p engineered exosome and an application of the miR-671-5p engineered exosome in treatment of Parkinson's disease. The miR-671-5p small nucleic acid molecule is transferred into the human umbilical cord blood mesenchymal stem cell exosome, so that the exosome is endowed with a specific treatment effect. Experiments show that astroglia inflammatory response in a PD model is closely related to PD related pathology, so that the astroglia inflammatory response becomes a potential target for treating PD. In mouse nigra transcriptome sequencing, the research group finds that chemotactic factors Cxc19 and Cxc110 of PD mouse astrocytes are remarkably increased, the miR-671-5p engineered exosome can remarkably reduce gene expression of the Cxc19 and the Cxc110, and after the miR-671-5p is knocked down, the expression quantity of the Cxc19 and the Cxc110 in the cells is remarkably increased. The miR-671-5p-rich engineered exosome disclosed by the invention has the potential of relieving neuroinflammatory response by regulating and controlling the expression of target genes Cxc19 and Cxc10, prevents the loss of dopaminergic neurons, and provides a promising method for relieving PD-related pathology.